Prelude Capital Management’s Xilio Therapeutics XLO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-11,600
Closed -$111K – 1669
2026
Q2
$111K Buy
+11,600
New +$96.9K 0.01% 1097
2024
Q2
– Sell
-2,107
Closed -$31.9K – 1539
2024
Q1
$31.9K Buy
+2,107
New +$20.3K ﹤0.01% 1268

Other funds holding XLO

Prelude Capital Management's XLO Position: Q3 2026 in Review

Prelude Capital Management sold out of Xilio Therapeutics (XLO) in Q3 2026, closing a stake of 11,600 shares — an estimated $111K sold.

Prelude Capital Management first reported a position in XLO in Q1 2024 and held it in 2 quarters. The position peaked at $111K in Q2 2026. 30 funds tracked by Wall St. Rank hold XLO as of Q3 2026.

  • Prelude Capital Management reported no remaining Xilio Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Prelude Capital Management sold 11,600 Xilio Therapeutics shares in Q3 2026, an estimated $111K.
  • Prelude Capital Management first reported a position in Xilio Therapeutics in Q1 2024 and held it in 2 quarters.
  • Prelude Capital Management's Xilio Therapeutics position peaked at $111K in Q2 2026.
  • 30 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q3 2026.

Based on Prelude Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.